Filing Flows › Lyell Immunopharma (LYEL) › Q1 2025
Lyell Immunopharma (LYEL) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Lyell Immunopharma (LYEL) reported revenue of $7K for the first quarter 2025 (Q1 2025), +133% from a year earlier and -36% from the quarter before.
Lyell Immunopharma, Q1 2025: revenue $7K (+133% year over year), net loss $52.2M, operating cash flow −$54.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7K | -36% | +133% |
| Operating profit | −$57.4M | — | — |
| Net earnings | −$52.2M | — | — |
| Operating cash flow | −$54.7M | — | — |
What changed
Revenue was $7K in Q1 2025, up 133% year over year and down 36% from the previous quarter.
Operating costs exceeded revenue by $57.4M, an operating margin of -819528.6%. Total costs grew 3% against revenue growth of 133%. The quarter ended with a net loss of $52.2M, narrower than the previous quarter's $191.9M loss.
Operating cash flow was −$54.7M. Non-cash charges added back $3.4M of depreciation and amortization and $6.0M of share-based compensation. Working capital and other items used $12.0M. Capital expenditures of $246K exceeded it, leaving free cash flow of −$55.0M.
Questions
What was Lyell Immunopharma's revenue in the first quarter 2025?
Lyell Immunopharma (LYEL) reported revenue of $7K for the first quarter 2025 (Q1 2025), +133% from a year earlier and -36% from the quarter before.
Source: Lyell Immunopharma 10-Q on SEC EDGAR.